Filtered By:
Condition: Mania
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 407 results found since Jan 2013.
Screening for obstructive sleep apnoea in high-risk patients with mood disorders
CONCLUSIONS: This pilot study showed an increased risk of OSA in patients with mood disorders. Psychiatric patients with identified risk factors should be routinely screened for obstructive sleep apnoea and referred to proper treatment.PMID:36528884
Source: Neuroendocrinology Letters - December 18, 2022 Category: Endocrinology Source Type: research
Deep brain stimulation for movement disorders after stroke: a systematic review of the literature
CONCLUSIONS: This is the first systematic review of DBS for poststroke movement disorders. Overall, most studies to date have been case reports and small series reporting heterogeneous patients and surgical strategies. This review suggests that DBS for movement disorders after a stroke has the potential to be effective and safe for diverse patients, and DBS may be a feasible option to improve function even years after a stroke.PMID:36308482 | DOI:10.3171/2022.8.JNS221334
Source: Journal of Neurosurgery - October 29, 2022 Category: Neurosurgery Authors: Mitch R Paro Michal Dyrda Srinath Ramanan Grant Wadman Stacey-Ann Burke Isabella Cipollone Cory Bosworth Sarah Zurek Patrick B Senatus Source Type: research
Use of low-dose quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator-controlled cohort study
World Psychiatry. 2022 Oct;21(3):444-451. doi: 10.1002/wps.21010.ABSTRACTAt standard doses used for schizophrenia or bipolar disorder, quetiapine has been associated with weight gain and increased levels of triglycerides, to-tal cholesterol and low-density lipoprotein (LDL) cholesterol, which are risk factors for cardiovascular morbidity and mortality. However, this drug is also commonly used off-label at low doses for anxiolytic or hypnotic purposes, and its cardiovascular safety at these doses is unknown. We aimed to assess the risk of major adverse cardiovascular events with use of low-dose quetiapine compared to use of...
Source: World Psychiatry - September 8, 2022 Category: Psychiatry Authors: Mikkel H øjlund Kjeld Andersen Martin T Ernst Christoph U Correll Jesper Hallas Source Type: research
